Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Labetalol

Klassificering: A

Preparat: Albetol, Labetalol S.A.L.F., Trandate

ATC kod: C07AG01

Substanser: labetalol, labetalolhydroklorid

Sammanfattning

Den blodtryckssänkande effekten av labetalol är likvärdig mellan könen.

Vid samma dos får kvinnor en påtagligt högre plasmakoncentration av labetalol än män. Det är framförallt koncentrationen av de inaktiva stereoisomererna som är högre hos kvinnor, medan koncentrationen av den aktiva beta-blockerande isomeren inte visar samma könsskillnad.

Additional information

Pharmacokinetics and dosing

A randomized, crossover study (14 men, 5 women) evaluated the impact of patient’s sex on labetalol kinetics. Patients had labetalol dosages titrated from 100 mg twice/day to a specific antihypertensive response. Despite receiving similar average dosages and having similar body weight, significant sex differences were seen in labetalol kinetics. Oral clearance was higher in men. Plasma concentrations were 80% higher in women than men, but the drug’s effect on blood pressure was similar in men and women. The dose-corrected for AUC for the beta-blocking R,R-labetalol was only 10% higher in women, while AUC for the other stereoisomers were 56-77% higher. Thus, the sex differences in labetalol kinetics seem to be due to differences in active alpha-blocking stereoisomers but not in beta-blocking stereoisomers [1].

Labetalol in women with pregnancy-induced hypertension was found to have shorter serum half-life but similar clearance, as compared with those of non-pregnant hypertensive and normotensive populations [2].

Effects

A small randomized study (14 men, 5 women) has shown that men and women achieved similar blood pressure reduction from labetalol, even though plasma concentration was much higher in women than men [1].

Adverse effects

Labetalol in women with pregnancy-induced hypertension was well tolerated by all patients with no adverse effects reported [2].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande labetalol (ATC-kod C07AG01) på recept i Sverige år 2018, totalt 6 534 kvinnor och 4 572 män. Det motsvarar 1,3 respektive 0,9 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 80 år och äldre hos båda könen [3].

Uppdaterat: 2019-05-27

Litteratursökningsdatum: 2019-05-16

Referenser

  1. Johnson JA, Akers WS, Herring VL, Wolfe MS, Sullivan JM. Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy. 2000;20:622-8. PubMed
  2. Rogers RC, Sibai BM, Whybrew WD. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1990;162:362-6. PubMed
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.] länk

Författare: Linnéa Karlsson Lind

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson